AMEDISYS sees a downgrade to Slightly Negative on account of less fundamental stars
The independent financial analyst theScreener just lowered the general evaluation of AMEDISYS (US), active in the Health Care Providers industry. As regards its fundamental valuation, the title now shows 0 out of 4 stars while market behaviour can be considered moderately risky. theScreener believes that the title remains under pressure due to the loss of a star(s) and downgrades its general evaluation to Slightly Negative. As of the analysis date February 23, 2021, the closing price was USD 280.27 and its target price was estimated at USD 231.98.Amedisys is a healthcare services company focused on providing care in the home. The company's operations involve servicing patients across the United States through its operating divisions: home health, hospice and personal care. The company's Home Health segment provides healthcare to help its patients recover from surgery or illness, live with chronic diseases, and prevent avoidable hospital readmissions. Hospice care is designed to provide comfort and support for those who are dealing with a terminal illness such as heart disease, pulmonary disease, Alzheimer's or cancer. Personal care provides assistance with the activities of daily living.
Empowering Investors
theScreener is the market leader for independent valuations of financial securities, equities, sectors and markets, and new funds. theScreener's ratings, analyses are used by leading banks, asset managers and financial portals. Approximately 10,000 workstations benefit from theScreener's services, with over millions of customer accounts actively analysed.
- Worldwide coverage: theScreener analyses cover around 6'500 Stocks, i.e 95% of the world Market Capitalization. theScreener state of art: We provide
- theScreener state of art: We provide easy to use and complete analyses over Stocks, including Fundamentals / Technical / Risk/ Peer / Alternatives analyses.
- For Research Pool community, we provide twice a week around 500 new equity analyses. We produce analyses about equities which have been upgraded or downgraded.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.